Abstract: Compounds are provided for use in the diagnosis and/or therapy of tumors and/or as immunosuppressive agent. The compounds are antibodies which bind to IL-4 receptors and IL-4 receptor-binding fragments thereof. A preferred compound is monoclonal antibody MR-6 produced by the hybridoma deposited at the European Collection of Animal Cell Cultures with the accession number 88033002. The invention also extends to the use of the compounds for in vitro removal of graft-versus-host reactive T-lymphocytes prior to bone marrow transplantation and to a novel protein of molecular weight 200,000 daltons functioning as a receptor for IL-4.
Type:
Grant
Filed:
June 7, 1995
Date of Patent:
December 5, 2000
Assignee:
Royal Postgraduate Medical School of Hammersmith Hospital
Abstract: The invention provides compounds for use in the diagnosis and/or therapy of tumors and/or as an immunosuppressant agent selected from the group consisting of antibodies which bind to IL-4 receptors and IL-4 receptor-binding fragments thereof. A preferred such compound is monoclonal antibody MR6 produced by the hybridoma deposited at the European Collection of Animal Cell Cultures with the accession number 88033002. The invention also extends to the use of the compounds for in vitro removal of graft-versus-host reactive T-lymphocytes prior to bone marrow transplantation and to a novel protein of molecular weight 200,000 daltons functioning as a receptor for IL-4.
Type:
Grant
Filed:
September 21, 1994
Date of Patent:
November 16, 1999
Assignee:
Royal Postgraduate Medical School of Hammersmith Hospital